Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chubb Ltd (CB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Chubb Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Chubb Ltd trades at $347.71 (market cap $134.37B). The key difference: Chubb Ltd is far larger — about 155.5× Amphastar Pharmaceuticals Inc's market cap, and Chubb Ltd pays a 1.17% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CB | |
|---|---|---|
Market Cap | $863.95M | $134.37B |
Sector | Health | Financials |
52-Week High | $30.81 | $363.50 |
52-Week Low | $16.87 | $268.20 |
Enterprise Value | $1.26B | $155.22B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Chubb (CB) trades at $350.31, down 1.05% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $7.26 beating estimates, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Recent news highlights leadership appointments and positive earnings coverage.
The outlook is positive, supported by consistent earnings beats, a 52.38% analyst buy rating, and a consensus price target of $366.83. Risks include macroeconomic sensitivity and competitive pressures in insurance. The stock presents a value opportunity with a P/E of 12.41 and robust cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
